The Birth of Masimo: How Project Stork and SET® Pulse Oximetry Revolutionized Neonatal Care
About Masimo
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and connectivity solutions. In 1995, Masimo debuted SET® Measure-through Motion and Low Perfusion™ pulse oximetry, estimated to be used on more than 100 million patients annually. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry, allowing noninvasive and continuous monitoring of additional physiologic parameters that previously could only be measured invasively, such as total hemoglobin (SpHb®). We continue to advance noninvasive monitoring, connectivity, and automation with innovations like the Root® patient monitoring and connectivity hub and the Patient SafetyNet™ supplemental remote monitoring solution.
“Improving patient outcomes, reducing the cost of care, and taking noninvasive monitoring to new sites and applications.™”
Masimo is committed to improving patient outcomes and reducing cost of care by working with dedicated hospital staff to convert healthcare institutions around the world to Masimo SET® pulse oximetry technology. We are accomplishing this goal through partnering with our patient monitoring companies and caregivers and creating innovative, cost-effective acquisition programs for Masimo SET® products for the benefit of the patients.
Four-wavelength near-infrared peripheral oximetry in cardiac surgery patients: a comparison between EQUANOX and O3. Ferraris A, Jacquet-Lagrèze M, Fellahi JL. J Clin Monit Comput. 2017 May 2 Link: https://pubmed.ncbi.nlm.nih.gov/28466202/
Absolute and Trend Accuracy of a New Regional Oximeter in Healthy Volunteers During Controlled Hypoxia. Redford D, Paidy S, Kashif F. Anesth Analg. 2014 Dec; 119(6):1315-1319. PubMed PMID: 25405692. Link: https://pubmed.ncbi.nlm.nih.gov/25405692/
Intraoperative effect of dexmedetomidine infusion during living donor liver transplantation: A randomized control trial.Sayed E, Yassen KA. Saudi J Anaesth. 2016 Jul-Sep;10(3):288-94.Link: https://pubmed.ncbi.nlm.nih.gov/27375383/
Comparison between two versions of the Patient State Index during propofol and sevoflurane anesthesia, with or without remifentanil.Kuizenga M.H., Colin P.J., Vereecke H.E.M., Struys M.M.R.F. Proceedings from Euroanaesthesia 2017, Geneva, Switzerland. Abstract #01AP07-4. Link: https://www.morressier.com/o/event/58ece711d462b80296c9d25b/article/58f5b031d462b80296c9d33a
Titration of Delivery and Recovery from Propofol, Alfentanil, and Nitrous Oxide Anesthesia.Drover D.R., Lemmens H.J., Pierce E.T., Plourde G., Loyd G., Ornstein E., Prichep L.S., Chabot R.J., Gugino L. Anesthesiology 2002; 97:82–9. Link: https://pubmed.ncbi.nlm.nih.gov/12131107/
Effects of sevoflurane and propofol on frontal electroencephalogram power and coherence.Akeju O, Westover MB, Pavone KJ, Sampson AL, Hartnack KE, Brown EN, Purdon PL. Anesthesiology. 2014 Nov;121(5):990-8. doi:10.1097/ALN.0000000000000436.Link: https://pubmed.ncbi.nlm.nih.gov/25233374/
Is The Patient State Analyzer With The Psarray2 A Cost-Effective Alternative To The Bispectral Index Monitor During The Perioperative Period?White P.F., Tang J., Ma H., Wender R.H., Sloninsky A., Kariger R. Anesth Analg. 2004 Nov;99(5):1429-35.Link: https://pubmed.ncbi.nlm.nih.gov/15502043/
A Comparison Of Patient State Index And Bispectral Index Values During The Perioperative Period.Chen X., Tang J., White P.F., Wender R.H., Ma H., Sloninsky A., Kariger R. Anesth Analg. 2002 Dec;95(6):1669-74.Link: https://pubmed.ncbi.nlm.nih.gov/12456436/
Advanced Monitoring Is Associated with Fewer Alarm Events During Planned Moderate Procedure-Related Sedation: A 2-Part Pilot Trial.Applegate RL 2nd, Lenart J, Malkin M, Meineke MN, Qoshlli S, Neumann M, Jacobson JP, Kruger A, Ching J, Hassanian M, Um M. Anesth Analg. 2016 Feb 1.Link: https://pubmed.ncbi.nlm.nih.gov/26836134/
